Already-licensed drugs could be trialed to potentially treat secondary brain cancer, new research finds

The largest review of papers for brain cancer that has spread from the lungs has found abnormalities in the brain cancer for which licensed drugs could be clinically trialed to find out if they could treat the disease. The research led by the University of Bristol and published in Neuro-Oncology Advances also found genetic differences between smokers and non-smokers. The paper is titled “Genomic landscape and actionable mutations of brain metastases derived from non-small cell lung cancer: a systematic review.”